

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING OF THE COMPANY BY A
DIRECTOR AND SUBSTANTIAL SHAREHOLDER

This is a voluntary announcement made by Biosino Bio-Technology and Science Incorporation (the “**Company**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces that the Board has been informed by Mr. Chen Peng (“**Mr. Chen**”), the Chairman, President, executive Director and substantial Shareholder of the Company, that during the period from 15 June 2026 to 14 July 2026, Mr. Chen acquired an aggregate of 4,300,176 domestic shares of the Company (the “**Domestic Shares**”) through Jingning Guoke Kangyi Enterprise Management Center LLP (景寧國科康儀企業管理中心(有限合夥)) (“**Guoke Kangyi**”) and Guoke Healthcare Innovation Research Institute (Hefei) Partnership (Limited Partnership) (國科健康院創新研究院(合肥)合夥企業(有限合夥)) (“**Guoke Healthcare**”) in off-market transactions, representing approximately 2.97% of the total number of issued shares of the Company (the “**Share(s)**”), at a total consideration of approximately RMB10.53 million (at a price ranging from RMB2.40 to RMB2.50 per Share).

Immediately following the above increase in shareholding and as at the date of this announcement, Mr. Chen, through (i) Guoke Kangyi and Guoke Healthcare, holds an aggregate of 15,630,510 Domestic Shares; and (ii) HK Zhixin Investment Co., Limited, holds 27,256,143 H shares of the Company (“**H Shares**”), representing an aggregate of approximately 29.64% of the total number of issued Shares (of which Domestic Shares and H Shares represent approximately 19.44% and 42.40% of the respective issued share classes, respectively).

Mr. Chen has expressed that the increase in shareholding reflects his confidence in the long-term development prospects and growth potential of the Company, and demonstrates his support for and commitment to the continuous development of the Company.

The Company will continue to monitor Mr. Chen's shareholding position in accordance with the relevant requirements and fulfill its information disclosure obligations in a timely manner. Based on the information available to the Company and to the best knowledge of the Board, as at the date of this announcement, the Company has a sufficient public float.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Peng
Chairman, President and Executive Director

Beijing, the PRC, 16 July 2026

As at the date of this announcement, the Board comprises:

Chairman, President and Executive Director

Mr. Chen Peng (陳鵬先生)

Vice chairman and Executive Director

Mr. Li Zhonghua (李忠華先生)

Executive Director

Mr. Chen Zhengyong (陳正永先生)

Non-executive Director

Ms. Kang Rui (康睿女士)

Independent non-executive Directors

Prof. Shen Jiangang (沈劍剛教授), Mr. Fan Xiaoliang (范曉亮先生), and Prof. Jin Tengchuan (金騰川教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Announcements” page on the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the Company’s website at www.zhongsheng.com.cn.